Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11941176 | 0.81 | ACE (0.54) | MMEACE | |
| SCHEMBL26512257 | 0.79 | MME (0.36) | MMEACECYP19A1TSHRCYP3A4 | |
| SCHEMBL5668771 | 0.76 | USP2 (0.40) | ALDH1A1TSHR | |
| SCHEMBL1677568 | 0.72 | FFAR1 (0.54) | CYP19A1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL16130561 | 0.71 | ACACB (0.49) | TSHR | |
| SCHEMBL1678301 | 0.70 | ACHE (0.41) | CYP19A1MAOAMAOBPTGS2ALDH1A1 | |
| SCHEMBL23895485 | 0.70 | GRM8 (0.49) | — | |
| SCHEMBL11166356 | 0.70 | AOC3 (0.37) | CYP19A1MAOAMAOBPTGS2ALDH1A1 | |
| SCHEMBL7438505 | 0.70 | CYP1A2 (0.45) | MMEALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL7255778 | 0.70 | CYP3A4 (0.43) | CYP19A1CYP3A4CYP2C19CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686116-B1 | PROCESS FOR PRODUCTION OF PYRIDYLETHYLTHIO COMPOUNDS, MODIFIED ION EXCHANGERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF BISPHENOLS | MITSUBISHI CHEM CORP (JP) | 2018-02-14 | — | — | EP | disclosed |
| US-8344152-B2 | Process for producing pyridylethylthio compound, modified ion exchanger and process for producing the same, and process for producing bisphenol compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-1686116-A1 | PROCESS FOR PRODUCTION OF PYRIDYLETHYLTHIO COMPOUNDS, MODIFIED ION EXCHANGERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF BISPHENOLS | Mitsubishi Chemical Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20060041145-A1 | Process for producing pyridylethylthio compound, modified ion exchanger and process for producing the same, and process for producing bisphenol compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041145-A1 | Process for producing pyridylethylthio compound, modified ion exchanger and process for producing the same, and process for producing bisphenol compound | PAH, SLC19A2, PLPBP | MME 4825/4885ACE 4417/4885CYP19A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.